UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934

Date of Report (Date of earliest event reported): October 26, 2010

Titan Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)				
Delaware	0-27436	94-3171940		
(State or Other Jurisdiction	(Commission	(IRS Employer		
of Incorporation)	File Number)	Identification No.)		
• •	Francisco, CA	94080		
(Address of Principal Executive Offices)		(Zip Code)		
Registrant's telep	ohone number, including area code: 6	550-244-4990		
(Former Na	me or Former Address, is Changed Since Last Ro	eport)		
** *	K filing is intended to simultaneously sa	tisfy the filing obligation of registrant under any		
Written communications pursuant to Rule 425 u	nder the Securities Act (17 CFR 230.42	5)		
Soliciting material pursuant to Rule 14a-12(b) us	nder the Exchange Act (17 CFR 240.14a	a-12(b))		
Pre-commencement communications pursuant to	Rule 14d-2(b) under the Exchange Act	t (17 CFR 240.14d-2(b))		
Pre-commencement communications pursuant to	Rule 13e-4(c) under the Exchange Act	(17 CFR 240.13e-4(c))		
	Delaware (State or Other Jurisdiction of Incorporation) 100 Oyster Point Blvd., Suite 505, South San I (Address of Principal Executive Offices) Registrant's telep (Former Na Check the appropriate box below if the Form 8- e following provisions: Written communications pursuant to Rule 425 u Soliciting material pursuant to Rule 14a-12(b) u Pre-commencement communications pursuant to	Delaware (State or Other Jurisdiction of Incorporation) (Commission File Number) 100 Oyster Point Blvd., Suite 505, South San Francisco, CA (Address of Principal Executive Offices) Registrant's telephone number, including area code: 6 (Former Name or Former Address, is Changed Since Last Reference to the Commission of Incorporation) (Former Name or Former Address, is Changed Since Last Reference to the Commission of Incorporation) (Former Name or Former Address, is Changed Since Last Reference to the Commission of Incorporation)		

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 26, 2010, Joachim Friedrich Kapp notified the registrant of his resignation from the board of directors, effectively immediately. On such date, he advised the registrant of his recent sale of 558,660 shares of the company's common stock.

SIGNATURES

	Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its	behalf
by	the undersigned hereunto duly authorized.	

Sunil Bhonsle, President		
By:	/s/ SUNIL BHONSLE	
TITAN PHARMACEUTICALS, INC.		

Dated: October 27, 2010